AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25483663 — intervention group
Group type: EXPERIMENTAL
Intervention: Palivizumab level; correlated with duration of RSVH, PICU stay, supplemental oxygen use, and mechanical ventilation use (P < 0.05).
Number of subjects: 48
Study 20504097 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral ERT (oestradiol hemihydrate 2 mg/day, Estrofem®)
Number of subjects: 45
Study 20504097 — intervention group
Group type: EXPERIMENTAL
Intervention: Transdermal ERT (oestradiol hemihydrate 0.1% gel 1.5 mg/day, Estreva®)
Number of subjects: 45
Study 20504097 — intervention group
Group type: COMPARATOR
Intervention: No hormone therapy (control)
Number of subjects: 45
Study 19502990 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-course HAART
Number of subjects: 0
Study 19502990 — intervention group
Group type: COMPARATOR
Intervention: ZDV/sdNVP
Number of subjects: 0
Study 18161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic clotting factor replacement therapy, cost USD 300,000 per patient per year, started after the first episode of joint bleeding early in life.
Number of subjects: 0
Study 18161260 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic treatment started after the first episode of joint bleeding.
Number of subjects: 0
Study 15321800 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA (0.63, 1.26, and 2.52 g/d)
Number of subjects: 0
Study 15321800 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-9,trans-11 CLA (0.59, 1.19, and 2.38 g/d)
Number of subjects: 0
Study 15321800 — intervention group
Group type: EXPERIMENTAL
Intervention: trans-10,cis-12 CLA
Number of subjects: 0
Study 15321800 — intervention group
Group type: EXPERIMENTAL
Intervention: cis-9,trans-11 CLA
Number of subjects: 0
Study 15321800 — intervention group
Group type: EXPERIMENTAL
Intervention: CLA supplementation (both isomers)
Number of subjects: 0
Study 11458439 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulsair (P), DeVilbiss, Sunrise Medical
Number of subjects: 17
Study 11458439 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxytron (O), Weinmann
Number of subjects: 17
Study 11458439 — intervention group
Group type: EXPERIMENTAL
Intervention: DOC‐2000 (D), TransTracheal Inc.
Number of subjects: 17
Study 11458439 — intervention group
Group type: COMPARATOR
Intervention: Continuous oxygen delivery (CONT)
Number of subjects: 17
Study 9706245 — intervention group
Group type: EXPERIMENTAL
Intervention: Ganciclovir alone or in combination with foscarnet
Number of subjects: 7
Study 8067225 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin
Number of subjects: 0
Study 8067225 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetaphan
Number of subjects: 0
Study 8067225 — intervention group
Group type: EXPERIMENTAL
Intervention: Prostaglandin E1
Number of subjects: 0
Study 2646975 — intervention group
Group type: EXPERIMENTAL
Intervention: Placebo
Number of subjects: 0
Study 2646975 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol
Number of subjects: 0
Study 2646975 — intervention group
Group type: COMPARATOR
Intervention: Soft drink control
Number of subjects: 0
Study 4904162 — intervention group
Group type: EXPERIMENTAL
Intervention: 50 mg of sustained release phenformin capsules administered twice daily
Number of subjects: 0
Study 4904162 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 30501926 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyanoacrylate tissue adhesive
Number of subjects: 120
Study 30501926 — intervention group
Group type: COMPARATOR
Intervention: Silk suture
Number of subjects: 120
Study 29091726 — intervention group
Group type: EXPERIMENTAL
Intervention: Sanitation promotion
Number of subjects: 181
Study 29091726 — intervention group
Group type: EXPERIMENTAL
Intervention: Handwashing promotion
Number of subjects: 181
Study 29091726 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined intervention
Number of subjects: 181
Study 29091726 — intervention group
Group type: COMPARATOR
Intervention: Control (neither intervention)
Number of subjects: 181
Study 26022965 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily PROactive instrument
Number of subjects: 236
Study 26022965 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical visit PROactive instrument
Number of subjects: 236
Study 24326395 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous 100 ng/ml ketamine
Number of subjects: 72
Study 24326395 — intervention group
Group type: EXPERIMENTAL
Intervention: 2 mg oral risperidone
Number of subjects: 72
Study 24326395 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 ng/ml ketamine plus 2 mg oral risperidone
Number of subjects: 72
Study 24326395 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 72
Study 21508131 — intervention group
Group type: EXPERIMENTAL
Intervention: Amiloride (20 mg)
Number of subjects: 16
Study 21508131 — intervention group
Group type: EXPERIMENTAL
Intervention: Furosemide (25 mg)
Number of subjects: 16
Study 21508131 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal amiloride-sensitive potential
Number of subjects: 16
Study 18054465 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin 400 mg single oral dose
Number of subjects: 12
Study 16585301 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral sildenafil (1 mg/kg every 6 hours)
Number of subjects: 13
Study 16585301 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 12963195 — intervention group
Group type: EXPERIMENTAL
Intervention: Off-pump surgery
Number of subjects: 52
Study 12963195 — intervention group
Group type: COMPARATOR
Intervention: On-pump surgery
Number of subjects: 52
Study 12963195 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 52
Study 10859628 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard suctioning procedure applied by the researcher
Number of subjects: 0
Study 10859628 — intervention group
Group type: COMPARATOR
Intervention: Control group suctioning procedure applied by nurses
Number of subjects: 0
Study 10225743 — intervention group
Group type: EXPERIMENTAL
Intervention: Polymyxin B immobilized fiber
Number of subjects: 0
Study 10225743 — intervention group
Group type: EXPERIMENTAL
Intervention: Charcoal hemoperfusion
Number of subjects: 0
Study 10225743 — intervention group
Group type: EXPERIMENTAL
Intervention: Plasma or whole blood exchange
Number of subjects: 0
Study 10225743 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous hemofiltration or hemodiafiltration
Number of subjects: 0
Study 1534991 — intervention group
Group type: EXPERIMENTAL
Intervention: Gemfibrozil
Number of subjects: 292
Study 1534991 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 292
Study 2580178 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril 100 mg
Number of subjects: 13
Study 2580178 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrochlorothiazide 25 mg
Number of subjects: 13
Study 2580178 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination of captopril and hydrochlorothiazide
Number of subjects: 13
Study 2580178 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study 31238517 — intervention group
Group type: EXPERIMENTAL
Intervention: Multifaceted, tailored intervention including nutrition intake magnets at patient bedsides, multidisciplinary hospital staff training, and foodservice system changes.
Number of subjects: 207
Study 27535752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 600 IU
Number of subjects: 58
Study 27535752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 2000 IU
Number of subjects: 58
Study 27535752 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin D3 4000 IU
Number of subjects: 58
Study 27535752 — intervention group
Group type: COMPARATOR
Intervention: Control (no vitamin D supplementation)
Number of subjects: 58
Study 27234632 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexible Policy
Number of subjects: 117
Study 27234632 — intervention group
Group type: COMPARATOR
Intervention: Standard Policy
Number of subjects: 117
Study 24773395 — intervention group
Group type: EXPERIMENTAL
Intervention: Mouth-to-face-shield ventilation
Number of subjects: 30
Study 24773395 — intervention group
Group type: COMPARATOR
Intervention: Mouth-to-pocket-mask ventilation
Number of subjects: 30
Study 22588333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fibrin tissue adhesive (Quixil)
Number of subjects: 70
Study 22588333 — intervention group
Group type: COMPARATOR
Intervention: Postoperative blood recovery and reinfusion (control group)
Number of subjects: 70
Study 19485844 — intervention group
Group type: EXPERIMENTAL
Intervention: Prospective screening for the predisposing genetic marker for abacavir hypersensitivity reactions
Number of subjects: 0
Study 19485844 — intervention group
Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study 17320744 — intervention group
Group type: EXPERIMENTAL
Intervention: Multi-slice computed tomography (MSCT)
Number of subjects: 197
Study 17320744 — intervention group
Group type: COMPARATOR
Intervention: Standard of care (SOC)
Number of subjects: 197
Study 15223977 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnesium chloride (MgCl2) 2.5 g daily
Number of subjects: 0
Study 15223977 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 12003703 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 0
Study 12003703 — intervention group
Group type: COMPARATOR
Intervention: Control group (no antihypertensive treatment)
Number of subjects: 0
Study 9823639 — intervention group
Group type: EXPERIMENTAL
Intervention: Two Redons (one subcutaneously and one subfascial)
Number of subjects: 158
Study 9823639 — intervention group
Group type: COMPARATOR
Intervention: Three Redons (conventional procedure)
Number of subjects: 158
Study 9823639 — intervention group
Group type: COMPARATOR
Intervention: One drain (subcutaneously or subfascial)
Number of subjects: 158
Study 7994795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin alone (Group A)
Number of subjects: 331
Study 7994795 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral 5-fluorouracil (5-FU) (Group B)
Number of subjects: 331
Study 7994795 — intervention group
Group type: EXPERIMENTAL
Intervention: Adriamycin and oral 5-FU (Group C)
Number of subjects: 331
Study 7994795 — intervention group
Group type: COMPARATOR
Intervention: Control group (Group D)
Number of subjects: 331
Study 2658615 — intervention group
Group type: EXPERIMENTAL
Intervention: Oculab BioPen
Number of subjects: 58
Study 2658615 — intervention group
Group type: COMPARATOR
Intervention: Ultrascan Digital B System IV
Number of subjects: 58
Study 1094994 — intervention group
Group type: EXPERIMENTAL
Intervention: Chloramphenicol 0.5% ophthalmic solution
Number of subjects: 0
Study 31619184 — intervention group
Group type: EXPERIMENTAL
Intervention: Medido medication dispenser
Number of subjects: 87
Study 31619184 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 87
Study 28108038 — intervention group
Group type: EXPERIMENTAL
Intervention: Laryngeal Mask Airway (LMA)
Number of subjects: 181
Study 28108038 — intervention group
Group type: COMPARATOR
Intervention: Endotracheal Tube
Number of subjects: 181
Study 26178502 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune nutrition group (containing essential fatty acids, omega‐3 fatty acids, energy 1.3 kcal/ml), n = 30
Number of subjects: 60
Study 26178502 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition group (self‐made homogenized diet 1.2 kcal/ml), n = 30
Number of subjects: 60
Study 26178502 — intervention group
Group type: EXPERIMENTAL
Intervention: Immune nutrition group
Number of subjects: 60
Study 26178502 — intervention group
Group type: COMPARATOR
Intervention: Standard nutrition group
Number of subjects: 60
Study 23795745 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-pressure pneumoperitoneum (7 mmHg)
Number of subjects: 20
Study 21459815 — intervention group
Group type: EXPERIMENTAL
Intervention: Short breastfeeding (4 months only)
Number of subjects: 618
Study 21459815 — intervention group
Group type: COMPARATOR
Intervention: Long breastfeeding (until the mother decided to stop)
Number of subjects: 618
Study 21459815 — intervention group
Group type: EXPERIMENTAL
Intervention: Weaned children (after 4 months)
Number of subjects: 618
Study 19358213 — intervention group
Group type: EXPERIMENTAL
Intervention: Test treatment
Number of subjects: 0
Study 19358213 — intervention group
Group type: COMPARATOR
Intervention: Active control
Number of subjects: 0
Study 16469155 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated soya protein 30 g daily
Number of subjects: 26
Study 16469155 — intervention group
Group type: COMPARATOR
Intervention: Milk protein 30 g daily (Control)
Number of subjects: 26
Study 15199083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day for 9 days) with olanzapine (10 mg single dose on day 4)
Number of subjects: 21
Study 15199083 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine (100 mg/day for 9 days) with clozapine (10 mg single dose on day 4)
Number of subjects: 21
Study 15199083 — intervention group
Group type: COMPARATOR
Intervention: Olanzapine alone (10 mg single dose)
Number of subjects: 21
Study 15199083 — intervention group
Group type: COMPARATOR
Intervention: Clozapine alone (10 mg single dose)
Number of subjects: 21
Study 11346244 — intervention group
Group type: EXPERIMENTAL
Intervention: Bundle-branch block (BBB) present
Number of subjects: 1239
Study 11346244 — intervention group
Group type: EXPERIMENTAL
Intervention: New appearance of bundle-branch block (n = 64)
Number of subjects: 1239
Study 11346244 — intervention group
Group type: COMPARATOR
Intervention: Bundle-branch block (n = 76)
Number of subjects: 1239
Study 9595177 — intervention group
Group type: EXPERIMENTAL
Intervention: TBF for hand warming
Number of subjects: 70
Study 9595177 — intervention group
Group type: COMPARATOR
Intervention: TBF for hand cooling
Number of subjects: 70
Study 9595177 — intervention group
Group type: COMPARATOR
Intervention: TBF for stabilization of hand temperature
Number of subjects: 70
Study 9595177 — intervention group
Group type: COMPARATOR
Intervention: Biofeedback to suppress alpha in the EEG
Number of subjects: 70
Study 8236405 — intervention group
Group type: EXPERIMENTAL
Intervention: ivermectin treatment
Number of subjects: 7148
Study 3317349 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 micrograms SmithKline Biologicals recombinant yeast-derived hepatitis B vaccine
Number of subjects: 90
Study 3317349 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 micrograms Merck Sharp & Dohme recombinant yeast-derived hepatitis B vaccine
Number of subjects: 90
Study 31746760 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Resolute stent (R-ZES) in CTO
Number of subjects: 5487
Study 31746760 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Resolute stent (R-ZES) in rec-TO
Number of subjects: 5487
Study 31746760 — intervention group
Group type: EXPERIMENTAL
Intervention: Zotarolimus-eluting Resolute stent (R-ZES) in non-TO
Number of subjects: 5487
Study 29769165 — intervention group
Group type: EXPERIMENTAL
Intervention: Potassium ferrate haemostatic patch (PFHP)
Number of subjects: 180
Study 29769165 — intervention group
Group type: COMPARATOR
Intervention: Control (no PFHP)
Number of subjects: 180
Study 27524882 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel (wPTX) 80 mg/m² intravenously on days 1, 8, and 15, every 4 weeks
Number of subjects: 66
Study 27524882 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wPTX) plus valproic acid (VPA) at 7.5 mg/kg twice daily
Number of subjects: 66
Study 27524882 — intervention group
Group type: COMPARATOR
Intervention: Weekly paclitaxel (wPTX)
Number of subjects: 66
Study 27524882 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly paclitaxel (wPTX) plus valproic acid (VPA)
Number of subjects: 66
Study 24716775 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer Assisted Telephone Interviews (CATI)
Number of subjects: 0
Study 24716775 — intervention group
Group type: COMPARATOR
Intervention: Self-administered paper surveys
Number of subjects: 0
Study 22670904 — intervention group
Group type: EXPERIMENTAL
Intervention: Vismodegib
Number of subjects: 41
Study 22670904 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 20819425 — intervention group
Group type: EXPERIMENTAL
Intervention: Mini-subvastus approach
Number of subjects: 68
Study 20819425 — intervention group
Group type: COMPARATOR
Intervention: Standard approach
Number of subjects: 68
Study 18503367 — intervention group
Group type: EXPERIMENTAL
Intervention: Pick-up method
Number of subjects: 92
Study 18503367 — intervention group
Group type: EXPERIMENTAL
Intervention: Basin dissection
Number of subjects: 92
Study 15668500 — intervention group
Group type: EXPERIMENTAL
Intervention: Antioxidant vitamin supplementation (500 mg vitamin C and 400 IU vitamin E daily)
Number of subjects: 100
Study 15668500 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 14504165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 1)
Number of subjects: 90
Study 14504165 — intervention group
Group type: EXPERIMENTAL
Intervention: Ondansetron 4 mg plus dexamethasone 8 mg after induction and placebo 12 h later (Group 3)
Number of subjects: 90
Study 14504165 — intervention group
Group type: COMPARATOR
Intervention: Dexamethasone 8 mg plus droperidol 1.25 mg after induction and droperidol 1.25 mg 12 h later (Group 2)
Number of subjects: 90
Study 10334518 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (semustine, vincristine, and fluorouracil (5-FU) - MOF regimen)
Number of subjects: 0
Study 10334518 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy (portal venous infusion of 5-FU)
Number of subjects: 0
Study 10334518 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant 5-FU and leucovorin (LV)
Number of subjects: 0
Study 10334518 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant 5-FU and LV compared with 5-FU and levamisole (LEV) and with the combination of 5-FU, LV, and LEV
Number of subjects: 0
Study 10334518 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjuvant chemotherapy overall
Number of subjects: 0
Study 10160470 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroergotamine mesylate (DHE)
Number of subjects: 100
Study 10160470 — intervention group
Group type: COMPARATOR
Intervention: Sumatriptan
Number of subjects: 100
Study 1743824 — intervention group
Group type: EXPERIMENTAL
Intervention: Vodka-tonic beverage containing a dose of vodka sufficient to induce a peak blood alcohol level of 0.05%
Number of subjects: 40
Study 1743824 — intervention group
Group type: COMPARATOR
Intervention: Tonic water (control)
Number of subjects: 40
Study 6459764 — intervention group
Group type: EXPERIMENTAL
Intervention: Piperacillin (2 g)
Number of subjects: 120
Study 6459764 — intervention group
Group type: COMPARATOR
Intervention: Penicillin G (4.8 X 10(6) U)
Number of subjects: 120
Study 31412832 — intervention group
Group type: EXPERIMENTAL
Intervention: Work Stress Questionnaire (WSQ) intervention group
Number of subjects: 271
Study 31412832 — intervention group
Group type: COMPARATOR
Intervention: Control group (treatment as usual)
Number of subjects: 271
Study 31412832 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 271
Study 27773349 — intervention group
Group type: EXPERIMENTAL
Intervention: Sexual Risk Event History Calendar (SREHC) assessment
Number of subjects: 181
Study 27773349 — intervention group
Group type: COMPARATOR
Intervention: Guidelines for Adolescent Preventive Services (GAPS) assessment
Number of subjects: 181
Study 25614446 — intervention group
Group type: EXPERIMENTAL
Intervention: First-line bevacizumab (15 mg/kg) plus carboplatin (AUC ×6) and paclitaxel (200 mg/m²) every 3 weeks (B + CP)
Number of subjects: 67
Study 25614446 — intervention group
Group type: EXPERIMENTAL
Intervention: Second-line bevacizumab plus erlotinib (150 mg/d; B + E)
Number of subjects: 67
Study 25012577 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel MD with lansoprazole (30 mg/day)
Number of subjects: 82
Study 25012577 — intervention group
Group type: EXPERIMENTAL
Intervention: 150 mg clopidogrel MD without lansoprazole
Number of subjects: 82
Study 25012577 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prasugrel MD with lansoprazole (30 mg/day)
Number of subjects: 82
Study 25012577 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg prasugrel MD without lansoprazole
Number of subjects: 82
Study 25012577 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo)
Number of subjects: 82
Study 22005941 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-reported financial pressures
Number of subjects: 1361
Study 22005941 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived financial burden
Number of subjects: 1361
Study 22005941 — intervention group
Group type: EXPERIMENTAL
Intervention: Presence of financial barriers
Number of subjects: 1361
Study 22005941 — intervention group
Group type: EXPERIMENTAL
Intervention: Being uninsured
Number of subjects: 1361
Study 22005941 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-adherence
Number of subjects: 1361
Study 19542996 — intervention group
Group type: EXPERIMENTAL
Intervention: Sevoflurane
Number of subjects: 80
Study 19542996 — intervention group
Group type: COMPARATOR
Intervention: Isoflurane
Number of subjects: 80
Study 17578365 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated estrogen 0.625 mg/day (n = 35)
Number of subjects: 132
Study 17578365 — intervention group
Group type: EXPERIMENTAL
Intervention: Intranasal 300 microg/day estradiol hemihydrate (n = 33)
Number of subjects: 132
Study 17578365 — intervention group
Group type: EXPERIMENTAL
Intervention: Percutaneous gel 1.5 mg/day estradiol hemihydrate (n = 32)
Number of subjects: 132
Study 17578365 — intervention group
Group type: COMPARATOR
Intervention: No treatment (control group, n = 32)
Number of subjects: 132
Study 15056208 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult's emotional displays during a 1‐hr delay
Number of subjects: 2
Study 15056208 — intervention group
Group type: EXPERIMENTAL
Intervention: Adult's emotional displays during a 3 min delay
Number of subjects: 2
Study 15477366 — intervention group
Group type: EXPERIMENTAL
Intervention: Testosterone enanthate (TE) 100 mg weekly intramuscularly plus levonorgestrel (LNG) 62.5 or 31.25 microg orally daily
Number of subjects: 7
Study 10692718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 100 mg
Number of subjects: 257
Study 10692718 — intervention group
Group type: EXPERIMENTAL
Intervention: Sumatriptan 50 mg
Number of subjects: 257